A5044031959- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Cancer-related Molecular Pathways
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- Ubiquitin and proteasome pathways
- Cancer-related molecular mechanisms research
- Genomics, phytochemicals, and oxidative stress
- Cancer Cells and Metastasis
- MicroRNA in disease regulation
- ATP Synthase and ATPases Research
- Heat shock proteins research
- Immunotherapy and Immune Responses
- Prostate Cancer Treatment and Research
- Mitochondrial Function and Pathology
- Estrogen and related hormone effects
- Neurobiology and Insect Physiology Research
- Immune cells in cancer
- RNA Research and Splicing
- Cancer-related gene regulation
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Pancreatic and Hepatic Oncology Research
- CRISPR and Genetic Engineering
- Cell Adhesion Molecules Research
Huazhong University of Science and Technology
2016-2025
Shanxi Academy of Medical Sciences
2022-2025
Shanxi Medical University
2022-2025
Tongji Hospital
2016-2025
Sidney Kimmel Cancer Center
2006-2023
Kaohsiung Medical University Chung-Ho Memorial Hospital
2023
Chinese Academy of Agricultural Sciences
2001-2023
Henan Cancer Hospital
2019-2022
Zhengzhou University
2019-2022
First Affiliated Hospital of Zhengzhou University
1997-2022
Decreased expression of specific microRNAs (miRNAs) occurs in human tumors, which suggests a function for miRNAs tumor suppression. Herein, levels the miR-17-5p/miR-20a miRNA cluster were inversely correlated to cyclin D1 abundance breast tumors and cell lines. MiR-17/20 suppressed cancer proliferation colony formation by negatively regulating translation via conserved 3′ untranslated region miRNA-binding site, thereby inhibiting serum-induced S phase entry. The cycle effect miR-17/20 was...
Acute myeloid leukemia (AML) is a common subtype and has poor prognosis. The risk of AML highly related to age. In the context population aging, comprehensive report presenting epidemiological trends evaluable for policy-marker allocate healthy resources.This study was based on Global Burden Disease 2017 database. We analyzed change incidence rate, death disability-adjusted life year (DALY) rate by calculating corresponding estimated annual percentage (EAPC) values. Besides, we investigated...
Abstract Background Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subset patients benefits from anti-PD-1/PD-L1 therapies. As negative regulator immunity, TGF-β impairs the efficacy induces drug resistance. Developing novel treatment strategy to simultaneously block PD-1/PD-L1 would be valuable enhance effect relieve Methods Based on...